(Corrects share price in second paragraph.)
Feb. 22 (Bloomberg) -- Can Fite Biopharma Ltd. headed for the biggest gain since November after the the U.S. Food and Drug Administration gave its CF102 drug to treat primary liver cancer orphan status.
The shares soared 7.6 percent, the most since Nov. 6, to 0.479 shekels at 1:12 p.m. in Tel Aviv. That gave the company a market value of 125 million shekels ($33 million).
--Editor: Claudia Maedler
To contact the reporter on this story: Gwen Ackerman in Jerusalem at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org